empty
 
 
de
Suche
Support
Sofortige Kontoeröffnung
Handelsplattform
Einzahlen / Auszahlen
Suche
Für Anfänger Für Trader Für Partner Machen Sie eine Pause Über uns
de
#DHR Zurück zur Liste #DXCM

Währungsrechner

Dynavax Technologies Corporation
15.49 USD
23 Jan 2026 22:59
Preisveränderung (% chg)
$-0.04
(-0.26%)
Schließung
Schließung

Schließungspreis, der vorherige Tag.
$15.63
Eröffnung
Eröffnung

Eröffnungspreis.
$15.67
Höchstpreis
Höchstpreis

Höchstpreis für den letzten Tag des Handels.
$15.64
Mindestpreis
Mindestpreis

Mindestpreis
$15.49
52 Wochen. max.
52 Wochen. max.

Höchstpreis für die letzten 52 Wochen.
$15.66
52 Wochen. min.
52 Wochen. min.

Mindestpreis für die letzten 52 Wochen.
$15.49
Archiv herunterladen
Buy
15.49
Sell
15.49
Open the chart in full screen view
Buy
15.49
Sell
15.49
Archiv herunterladen
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Können Sie momentan nicht telefonieren?
Dann stellen Sie Ihre Frage im Chat.